Brain arteriovenous malformations represent complex vascular lesions characterized by abnormal direct connections between arterial feeders and venous drainages. These niduses lack an intervening capillary bed, which exposes thin-walled draining veins to elevated arterial pressures. Consequently, patients face an ongoing annual risk of intracranial hemorrhage, intractable seizures, and progressive focal neurological deficits. For decades, neurosurgeons have utilized microsurgical resection as the definitive gold standard to achieve complete angiographic cure. However, managing high-grade or deeply seated lesions poses formidable technical challenges. To mitigate intraoperative blood loss and optimize surgical margins, interventional teams frequently perform preoperative embolization before surgical excision. Despite its widespread clinical adoption, the actual therapeutic benefit of this staged strategy remains a subject of considerable debate within the neurovascular community.

Pathophysiology and Rationale for Preoperative Embolization

The primary rationale for employing preoperative embolization lies in reducing the hemodynamic complexity of the vascular nidus before craniotomy. Neurointerventionalists selectively catheterize arterial feeders and deploy liquid embolic agents, such as ethylene vinyl alcohol copolymer or n-butyl cyanoacrylate, to occlude deep feeding vessels. Consequently, this intervention aims to diminish intranidal pressure, decrease intraoperative hemorrhage, and delineate clearer dissection planes for the operating neurosurgeon. Additionally, targeted embolization can selectively eliminate high-risk angioarchitectural features, including associated intranidal or flow-related feeding artery aneurysms. However, endovascular occlusion of high-flow shunts can also cause abrupt hemodynamic shifts within adjacent normal brain parenchyma. These alterations occasionally precipitate normal perfusion pressure breakthrough edema, occlusive hyperemia, or acute nidus rupture prior to planned surgical excision. Therefore, the theoretical advantages of adjunctive endovascular therapy must always be weighed carefully against procedural risks.

Findings from the Multicentre Propensity-Matched Cohort

To evaluate the actual clinical utility of adjunctive endovascular therapy, investigators from the Multicenter International Study for Treatment of Brain AVMs consortium conducted a comprehensive subanalysis. The researchers retrospectively evaluated 486 patients who underwent microsurgical resection between January 2010 and December 2023. Specifically, the cohort comprised 245 patients treated with microsurgery alone and 241 patients who underwent multimodal management involving preoperative embolization followed by surgery. Because baseline clinical characteristics and Spetzler-Martin grades often differ significantly between treatment arms, investigators employed robust propensity score matching. This statistical methodology yielded 288 balanced patients, with exactly 144 individuals in each cohort. The primary investigative endpoints were complete angiographic lesion obliteration and long-term functional recovery, measured by the modified Rankin Scale. Secondary outcomes included perioperative complication rates, overall mortality, postsurgical hemorrhage, and total duration of hospitalization.

Analysis of Obliteration and Functional Recovery

The comparative findings after propensity score matching revealed that both treatment paradigms achieved exceptional rates of complete anatomical cure. Overall, complete AVM obliteration reached 97% across the matched cohort, showing no statistically significant difference between the microsurgery-alone and the embolization-assisted groups. Similarly, functional neurological outcomes at the final follow-up were remarkably comparable between both clinical arms. Specifically, favorable functional recovery, defined as a modified Rankin Scale score of 0 to 2, was attained by 83% of patients in the microsurgery-only group and 84% in the embolization group. Moreover, the rates of postsurgical lesion recurrence, residual nidus requiring retreatment, and postoperative hemorrhage remained virtually identical. These results clearly demonstrate that routine endovascular occlusion of feeding arteries does not confer an incremental advantage regarding curative resection or long-term functional independence in matched patient populations.

Safety Profiles, Complications, and Hospitalization Metrics

Evaluating safety endpoints revealed that adding endovascular procedures introduces distinct considerations without lowering aggregate perioperative morbidity. Overall complication rates were similar between the cohorts, occurring in 24% of patients receiving preoperative embolization and 22% of those undergoing upfront microsurgery. In addition, all-cause mortality rates showed no statistically significant disparity between the two arms, recorded at 4.9% versus 2.1%, respectively. Nevertheless, the study highlighted a distinct difference in resource utilization and inpatient care. Patients undergoing multimodal staged therapy experienced a significantly longer median hospital stay of 9 days, compared with 7 days for those treated with microsurgery alone. This increased duration reflects the staged timing between endovascular intervention and subsequent craniotomy, alongside additional monitoring required for post-embolization neurological changes, access-site management, and procedural recovery.

Clinical Implications for Multidisciplinary Neurovascular Practice

These robust multicentre findings urge multidisciplinary neurovascular teams to re-examine the routine utilization of preoperative embolization for all surgically managed lesions. While embolization remains an indispensable adjunct for specific high-risk lesions with inaccessible deep feeders, routine non-selective application offers limited measurable benefit. Furthermore, performing staged endovascular procedures increases overall cumulative procedural risks, exposure to radiation, and healthcare costs while extending hospital stays. Clinicians should therefore reserve endovascular intervention for carefully selected anatomical scenarios where targeted feeder occlusion decisively facilitates surgical safety. Comprehensive case discussions within neurovascular boards must balance the anatomical benefits against potential complications to optimize individual patient care.

Frequently Asked Questions

What is the primary objective of preoperative embolization in AVM management?

The main objective is to selectively occlude deep or high-flow arterial feeding vessels using liquid embolic agents. This targeted reduction in intranidal blood flow aims to decrease intraoperative hemorrhage, demarcate surgical dissection planes, and facilitate safer microsurgical resection during craniotomy.

Does preoperative embolization improve long-term functional neurological outcomes?

Current multicentre propensity-matched evidence indicates that adjunctive embolization does not significantly improve long-term functional outcomes or complete obliteration rates compared with microsurgery alone. Both approaches demonstrate comparable rates of neurological independence and low post-treatment recurrence in appropriately selected patients.

Why does preoperative embolization lead to longer hospital stays?

Staged multimodal management necessitates sequential interventions, requiring separate procedural scheduling, distinct post-embolization neurological observation periods, access-site monitoring, and subsequent postoperative recovery. Consequently, this cumulative staging naturally extends the overall inpatient duration compared to a single upfront microsurgical resection.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Salim H et al. Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching. J Neurol Neurosurg Psychiatry. 2025 Jul 16. doi: 10.1136/jnnp-2024-334974. PMID: 39915091.

Derdeyn CP et al. Management of Brain Arteriovenous Malformations: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(8):e200-e224.

van Beijnum J et al. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011;306(18):2011-2019.